Investor alert: gpm commences investigation on behalf of davita healthcare partners, inc. investors

Los angeles--(business wire)--glancy prongay & murray llp (“gpm”) announces that it is investigating potential claims on behalf of investors of davita healthcare partners, inc. ("davita" or the "company") (nyse:dva), concerning the company and its officers’ possible violations of federal securities laws and/or breaches of fiduciary duty. please contact lesley portnoy at 888-773-9224 or 310-201-9150, or at shareholders@glancylaw.com to discuss this matter. if you inquire by email, please include your mailing address, telephone number, and number of shares purchased. on february 11, 2016, post-market, the company disclosed that it had received a civil investigative demand (cid) from the u.s. attorney's office for the northern district of texas regarding a false claims act investigation into allegations that it submitted false claims to the government for prescription drug reimbursement dating back to january 1, 2006. on this news, the company's shares fell $1.99, or 3.18%, to $60.58 post-market on february 11, 2016. if you purchased shares of davita, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact lesley portnoy, esquire, of glancy prongay & murray llp, 1925 century park east, suite 2100, los angeles, california 90067 at 310-201-9150, toll-free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. if you inquire by email please include your mailing address, telephone number and number of shares purchased. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
DVA Ratings Summary
DVA Quant Ranking